Periaqueductal Gray in Analgesia
Introduction <table class="infobox infobox-cell"> <tr> <th class="infobox-header" colspan="2">Periaqueductal Gray in Analgesia</th> </tr> <tr> <td class="label">Category </td> <td>Pain Modulation</td> </tr> <tr> <td class="label">Location </td> <td>Midbrain, surrounding the cerebral aqueduct</td> </tr> <tr> <td class="label">Cell Type </td> <td>Mixed neuronal populations (glutamatergic, GABAergic, serotonergic)</td> </tr> <tr> <td class="label">Function </td> <td>Endogenous pain control, opioid-mediated analgesia</td> </tr> </table>
Periaqueductal Gray In Analgesia is an important cell type in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
The periaqueductal gray (PAG) is a midbrain structure that serves as the central hub for endogenous pain modulation and represents a critical interface between emotional and sensory aspects of pain processing. [@bandler2000]
Overview
Anatomical Organization The PAG is organized into four longitudinal columns that subserve distinct functions:
...
Periaqueductal Gray in Analgesia
Introduction <table class="infobox infobox-cell"> <tr> <th class="infobox-header" colspan="2">Periaqueductal Gray in Analgesia</th> </tr> <tr> <td class="label">Category </td> <td>Pain Modulation</td> </tr> <tr> <td class="label">Location </td> <td>Midbrain, surrounding the cerebral aqueduct</td> </tr> <tr> <td class="label">Cell Type </td> <td>Mixed neuronal populations (glutamatergic, GABAergic, serotonergic)</td> </tr> <tr> <td class="label">Function </td> <td>Endogenous pain control, opioid-mediated analgesia</td> </tr> </table>
Periaqueductal Gray In Analgesia is an important cell type in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
The periaqueductal gray (PAG) is a midbrain structure that serves as the central hub for endogenous pain modulation and represents a critical interface between emotional and sensory aspects of pain processing. [@bandler2000]
Overview
Anatomical Organization The PAG is organized into four longitudinal columns that subserve distinct functions:
dorsolateral/lateral column (lPAG) : Processes somatic and visceral pain, activates defensive behaviors
ventrolateral column (vlPAG) : Mediates opioid analgesia, fear freezing, and autonomic regulation
dorsomedial column (dmPAG) : Associates with aversion and panic responses
lateral/dorsolateral (lateral PAG) : Coordinates pain modulation with motor outputs
The PAG receives dense projections from:
Spinal cord dorsal horn (pain signals)
Hypothalamus (emotional and autonomic integration)
Amygdala (fear and emotional pain)
Prefrontal [cortex](/brain-regions/cortex) (cognitive pain modulation)
Parabrachial nucleus (visceral sensory information)
Efferent Outputs Descending projections from the PAG target:
Rostral ventromedial medulla (RVM)
Dorsal horn of the spinal cord
Nucleus tractus solitarius (NTS)
Locus coeruleus (noradrenergic pain modulation)
Neurochemistry of Analgesia
Opioid Signaling The PAG contains high concentrations of endogenous opioids including:
Enkephalins : Met- and Leu-enkephalin
Endorphins : β-endorphin from periaqueductal [neurons](/entities/neurons)
Dynorphins : Found in specific subpopulations
Opioid receptor activation (primarily μ-opioid receptors) hyperpolarizes PAG neurons via G-protein mediated potassium channel opening, reducing GABAergic inhibition of output neurons and enabling descending inhibition.
Monoamine Systems
Serotonin (5-HT) : PAG 5-HT neurons project to RVM and spinal cord
Norepinephrine : Co-released from locus coeruleus projections
Both contribute to non-opioid analgesic mechanisms
Excitatory Amino Acids
Glutamate : Acts via NMDA and AMPA receptors
Substance P : Co-transmitter in pain pathways
CGRP : Calcitonin gene-related peptide in migraine mechanisms
Descending Pain Modulation
The Pain Facilitation/Inhibition Balance The PAG-RVM-spinal cord axis operates as a bidirectional system:
Inhibition Pathway:
Noxious stimuli activate PAG neurons
PAG projects to RVM
RVM sends serotonergic and noradrenergic fibers to dorsal horn
Released 5-HT and NE inhibit dorsal horn nociceptive transmission Facilitation (when maladaptive):
Prolonged pain can shift PAG-RVM function to facilitation
Contributes to chronic pain states
May underlie opioid-induced hyperalgesia
Clinical Significance
Migraine The PAG plays a central role in migraine pathophysiology:
Dysfunctional Descending Inhibition : Reduced PAG activity in chronic migraineurs
Brainstem Aura : Nucleus cuneiformis and PAG activation correlate with migraine aura
Triptan Mechanism : 5-HT1B/1D agonists may act partially through PAG modulation
Allodynia : Central sensitization involves PAG-RVM facilitation
Chronic Pain Disorders
Fibromyalgia : Reduced PAG gray matter volume and altered functional connectivity
Chronic Daily Headache : Abnormal PAG resting state activity
Neuropathic Pain : Loss of PAG-mediated inhibition
Opioid Analgesia
Tolerance Development : Chronic opioid exposure reduces PAG analgesic efficacy
Physical Dependence : PAG opioid receptor downregulation contributes
Opioid-induced Hyperalgesia : Paradoxical pain sensitization via PAG mechanisms
Withdrawal : PAG hyperactivity contributes to withdrawal symptoms
Parkinson's Disease
PAG dysfunction contributes to non-motor symptoms
Pain processing alterations in PD patients
Deep brain stimulation effects may involve PAG modulation
Neurodegenerative Disease Connections
Alzheimer's Disease
PAG receives cholinergic projections from pedunculopontine nucleus
Cholinergic loss in AD may impair PAG-mediated analgesia
Pain detection deficits in advanced AD may involve PAG
Amyotrophic Lateral Sclerosis
Respiratory dysfunction involves medullary respiratory centers
PAG contributes to automatic breathing control
Dysautonomia in ALS includes PAG-mediated functions
Therapeutic Targeting
Deep Brain Stimulation
PAG-DBS investigated for refractory pain
May restore descending inhibition balance
Pharmacological Approaches
μ-opioid agonists : Morphine, fentanyl (PAG-mediated)
Serotonin-norepinephrine reuptake inhibitors : Duloxetine (enhance descending inhibition)
Gabapentinoids : Modulate PAG-RVM axis
Non-invasive Techniques
Transcranial Magnetic Stimulation : Can modulate PAG activity
Meditation/Mindfulness : Increases PAG functional connectivity
Research Methods
fMRI : Pain-induced PAG activation
PET : Opioid receptor binding studies
Lesion Studies : PAG role in analgesia
Optogenetics : Circuit-specific manipulation
Background The study of Periaqueductal Gray In Analgesia has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
External Links
[NeuroNames](https://neuromorphics.org)
[Allen Brain Atlas](https://mouse.brain-map.org)
[Human Connectome Project](https://www.humanconnectome.org/)
Show full description